Ionis Pharmaceuticals, Inc. has received $-0.2 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 8 Financial Advisor in the Stock Trading Firms. Among 8 Analysts, Bottom line EPS Estimate for the current quarter is $-0.42 while the top line estimate is $0.02 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 66.31%.
Ionis Pharmaceuticals, Inc. results fell short with a surprise EPS of -14.29% or $-0.01. The Actual EPS was $0.06 compared to the Estimated EPS of $0.07 during its most recent quarterly earnings.
In the last quarter, Ionis Pharmaceuticals, Inc. reported Annual Earnings of $0.06. Based on the filings, last years Annual Earnings was, $-0.74. In the last Quarter, IONS reported a surprise Earnings per Share of -14.29% . The consensus estimate for current quarter is $-0.2 and for the current fiscal year, the estimate is $-1.13. For the Next fiscal year, the estimate is $-0.77 based on the consensus.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) : On Tuesday heightened volatility was witnessed in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) which led to swings in the share price. The stock opened for trading at $41.12 and hit $44.61 on the upside , eventually ending the session at $44.5, with a gain of 6.43% or 2.69 points. The heightened volatility saw the trading volume jump to 1,853,390 shares. The 52-week high of the share price is $57 and the company has a market cap of $5,394 million. The 52-week low of the share price is at $19.5927 .
Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.